Historical Valuation
Kura Oncology Inc (KURA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.91 is considered Undervalued compared with the five-year average of -6.57. The fair price of Kura Oncology Inc (KURA) is between 10877.77 to 10884.09 according to relative valuation methord. Compared to the current price of 9.97 USD , Kura Oncology Inc is Undervalued By 99.91%.
Relative Value
Fair Zone
10877.77-10884.09
Current Price：9.97
99.91%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Kura Oncology Inc (KURA) has a current Price-to-Book (P/B) ratio of 3.71. Compared to its 3-year average P/B ratio of 2.38 , the current P/B ratio is approximately 55.54% higher. Relative to its 5-year average P/B ratio of 2.37, the current P/B ratio is about 56.19% higher. Kura Oncology Inc (KURA) has a Forward Free Cash Flow (FCF) yield of approximately 9.24%. Compared to its 3-year average FCF yield of -4.52%, the current FCF yield is approximately -304.49% lower. Relative to its 5-year average FCF yield of -6.27% , the current FCF yield is about -247.32% lower.
P/B
Median3y
2.38
Median5y
2.37
FCF Yield
Median3y
-4.52
Median5y
-6.27
Competitors Valuation Multiple
AI Analysis for KURA
The average P/S ratio for KURA competitors is 18521.22, providing a benchmark for relative valuation. Kura Oncology Inc Corp (KURA.O) exhibits a P/S ratio of 3.91, which is -99.98% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for KURA
1Y
3Y
5Y
Market capitalization of KURA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KURA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KURA currently overvalued or undervalued?
Kura Oncology Inc (KURA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.91 is considered Undervalued compared with the five-year average of -6.57. The fair price of Kura Oncology Inc (KURA) is between 10877.77 to 10884.09 according to relative valuation methord. Compared to the current price of 9.97 USD , Kura Oncology Inc is Undervalued By 99.91% .
What is Kura Oncology Inc (KURA) fair value?
KURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kura Oncology Inc (KURA) is between 10877.77 to 10884.09 according to relative valuation methord.
How does KURA's valuation metrics compare to the industry average?
The average P/S ratio for KURA's competitors is 18521.22, providing a benchmark for relative valuation. Kura Oncology Inc Corp (KURA) exhibits a P/S ratio of 3.91, which is -99.98% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Kura Oncology Inc (KURA) as of Jan 09 2026?
As of Jan 09 2026, Kura Oncology Inc (KURA) has a P/B ratio of 3.71. This indicates that the market values KURA at 3.71 times its book value.
What is the current FCF Yield for Kura Oncology Inc (KURA) as of Jan 09 2026?
As of Jan 09 2026, Kura Oncology Inc (KURA) has a FCF Yield of 9.24%. This means that for every dollar of Kura Oncology Inc’s market capitalization, the company generates 9.24 cents in free cash flow.
What is the current Forward P/E ratio for Kura Oncology Inc (KURA) as of Jan 09 2026?
As of Jan 09 2026, Kura Oncology Inc (KURA) has a Forward P/E ratio of -4.11. This means the market is willing to pay $-4.11 for every dollar of Kura Oncology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kura Oncology Inc (KURA) as of Jan 09 2026?
As of Jan 09 2026, Kura Oncology Inc (KURA) has a Forward P/S ratio of 3.91. This means the market is valuing KURA at $3.91 for every dollar of expected revenue over the next 12 months.